Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Among authors: allegretti jr. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Outcomes After Dose Intensification of Risankizumab for Crohn's Disease.
Dalal RS, Cabral HJ, Carlin A, Ilse MP, Allegretti JR. Dalal RS, et al. Among authors: allegretti jr. Clin Gastroenterol Hepatol. 2024 Dec 9:S1542-3565(24)01067-X. doi: 10.1016/j.cgh.2024.09.039. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39662691 No abstract available.
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial.
Allegretti JR, Kelly CR, Louie T, Fischer M, Hota S, Misra B, Van Hise NW, Yen E, Bullock JS, Silverman M, Davis I, McGill SK, Pardi DS, Orenstein R, Grinspan A, El-Nachef N, Feuerstadt P, Borody TJ, Khanna S, Budree S, Kassam Z. Allegretti JR, et al. Gastroenterology. 2024 Oct 2:S0016-5085(24)05536-7. doi: 10.1053/j.gastro.2024.09.030. Online ahead of print. Gastroenterology. 2024. PMID: 39366468
Diet and Microbiome-Directed Therapy 2.0 for IBD.
Ananthakrishnan AN, Whelan K, Allegretti JR, Sokol H. Ananthakrishnan AN, et al. Among authors: allegretti jr. Clin Gastroenterol Hepatol. 2024 Jul 9:S1542-3565(24)00599-8. doi: 10.1016/j.cgh.2024.05.049. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38992408 Review.
Challenges in IBD Research 2024: Pragmatic Clinical Research.
Allegretti JR, Bordeianou LG, Damas OM, Eisenstein S, Greywoode R, Minar P, Singh S, Harmon S, Lisansky E, Malone-King M, Litwin NS, Weaver A, Heller CA, Moss AC, Adler J. Allegretti JR, et al. Inflamm Bowel Dis. 2024 May 23;30(Supplement_2):S55-S66. doi: 10.1093/ibd/izae083. Inflamm Bowel Dis. 2024. PMID: 38778623 Review.
140 results